Tuberculosis (TB) is an acute or chronic infection caused by Mycobacterium tuberculosis and is today, the leading cause of death from a single infectious pathogen. Since the outbreak of HIV, the occurrence of tuberculosis has increased dramatically and the World Health Organisation has declared TB a global emergency. This article highlights the patenting trends in this area and comments on compounds which are currently under preclinical evaluation or in Phase I or II clinical trials.